Quarterly report · Q2
6856.TEDINET S100RNOS
Period2023-01-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥131.1bn | 2023-01-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥270.1bn | 2022-01-01 → 2022-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥115.0bn | 2022-01-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥17.8bn | 2023-01-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥16.3bn | 2022-01-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥18.1bn | 2023-01-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥46.9bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.8bn | 2022-01-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥24.4bn | 2023-01-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥16.8bn | 2022-01-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥19.0bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥34.1bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥11.2bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥19.0bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥11.2bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥435.3bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥416.7bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥398.4bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥168.4bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥175.9bn | at 2022-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥266.8bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥240.8bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥224.6bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥127.7bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥139.9bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥127.0bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥138.8bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥139.3bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥133.9bn | at 2021-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥3.6bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥34.0bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.3bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥10.7bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.1bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥18.6bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥22.4bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.9bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥449.87 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥128.88 | 2023-04-01 → 2023-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥807.06 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥266.31 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥130.72 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥447.66 | 2023-01-01 → 2023-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥802.89 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥264.93 | 2022-01-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 61.1% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.6% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.2% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E01901-000Automotivereportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥30.5bn |
| jpcrp040300-q2r_E01901-000Automotivereportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥30.5bn |
| jpcrp040300-q2r_E01901-000Automotivereportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥2.2bn |
| jpcrp040300-q2r_E01901-000Medical Diagnosticsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥15.6bn |
| jpcrp040300-q2r_E01901-000Medical Diagnosticsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥15.6bn |
| jpcrp040300-q2r_E01901-000Medical Diagnosticsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥178m |
| jpcrp040300-q2r_E01901-000Process And Environmentalreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥11.3bn |
| jpcrp040300-q2r_E01901-000Process And Environmentalreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥11.3bn |
| jpcrp040300-q2r_E01901-000Process And Environmentalreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥916m |
| jpcrp040300-q2r_E01901-000Scientificreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥17.4bn |
| jpcrp040300-q2r_E01901-000Scientificreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥17.4bn |
| jpcrp040300-q2r_E01901-000Scientificreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥213m |
| jpcrp040300-q2r_E01901-000Semiconductorreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥56.2bn |
| jpcrp040300-q2r_E01901-000Semiconductorreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥56.2bn |
| jpcrp040300-q2r_E01901-000Semiconductorreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥18.7bn |
| jpcrp040300-q2r_E01901-000Automotivereportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥25.7bn |
| jpcrp040300-q2r_E01901-000Automotivereportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥25.7bn |
| jpcrp040300-q2r_E01901-000Automotivereportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥1.8bn |
| jpcrp040300-q2r_E01901-000Medical Diagnosticsreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥13.7bn |
| jpcrp040300-q2r_E01901-000Medical Diagnosticsreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥13.7bn |
| jpcrp040300-q2r_E01901-000Medical Diagnosticsreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥162m |
| jpcrp040300-q2r_E01901-000Process And Environmentalreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥10.2bn |
| jpcrp040300-q2r_E01901-000Process And Environmentalreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥10.2bn |
| jpcrp040300-q2r_E01901-000Process And Environmentalreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥638m |
| jpcrp040300-q2r_E01901-000Scientificreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥16.0bn |
| jpcrp040300-q2r_E01901-000Scientificreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥16.0bn |
| jpcrp040300-q2r_E01901-000Scientificreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥765m |
| jpcrp040300-q2r_E01901-000Semiconductorreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥49.4bn |
| jpcrp040300-q2r_E01901-000Semiconductorreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥49.4bn |
| jpcrp040300-q2r_E01901-000Semiconductorreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥16.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 565
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes business combinations quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |